Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease

Lancet

Volumn 355, Issue 9216, 2000, Pages 1696-1697

  Adalsteinsson, E ^a   Sullivan, E V ^a   Kleinhans, N ^a   Spielman, D M ^a   Pfefferbaum, A ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SRI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; N ACETYLASPARTIC ACID;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN NERVE CELL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DETERIORATION; DISEASE SEVERITY; FEMALE; GRAY MATTER; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCORING SYSTEM; WHITE MATTER;

EID: 0034643639     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02246-7     Document Type: Article

References (5)

1. Tallan HH. Studies on the distribution of N-acetyl-L-aspartate acid in brain. J Biol Chem 1956; 224: 41-45.
2. Pfefferbaum A, Adalsteinsson A, Spielman D, et al. In vivo brain concentrations of N-acetyl compounds, creatinine and chlorine in Alzheimer's disease. Arch Gen Psychiatry 1999; 56: 185-92.
3. Mohanakrishnan P, Fowler AH, Vonsattel JP, et al. An in vitro H-1 nuclear magnetic resonance study of the temproparietal cortex of Alzheimer brains. Exp Brain Res 1995; 102: 503-10.
4. Petroff OAC, Pleban LA, Spencer DD. Symbiosis between in vivo and in vitro NMR spectroscopy; the creatine, N-acetylasparate, glutamate and GABA content of the epileptic human brain. Magnetic Resonance Imaging 1995; 13: 1197-211.
5. Mattis S. Dementia rating scale (DRS) professional manual. Odessa, FL: Psychological Assessment Resources, Inc, 1988.